Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group Group Publications

Since August 2008, the following Group articles were published:

Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA. Quality of life outcomes for adjuvant chemotherapy in early stage non-small-cell lung cancer: Results from a randomized trial, JBR.10 (ONLINE). J Clin Oncol 2008.

Chi KN, Seymour L. Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino. Ann Oncol 19: 1813-4, 2008. (IND.167)

Goffin JR, Tu D. Phase II stopping rules that employ response rates and early progression. J Clin Oncol 26: 3715-20, 2008.

Mitry E, Fields ALA, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Cutsem EV, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A pooled analysis of two randomzied trials (ONLINE). J Clin Oncol 2008. (CO.7)

NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care
improves survival in advanced non-small-cell lung cancer: A systematic review and
meta-analysis of individual patient data from 16 randomized controlled trials.
J Clin Oncol 26: 4617-25, 2008. (BR.5)

Oza AM, Eisenhauer EA, Elit L, Cutz J-C, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 26: 4319-25, 2008.

Parulekar WR, McKenzie M, Chi KN, Klotz L, Catton C, Brundage M, Ding K, Hiltz A, Meyer R, Saad F. Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the Canadian Cancer Trials Group. Current Oncology 15: 14-9, 2008. (PR.11/PR.12/PR.13)

Zhu C-Q, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS. Role of KRAS and EGFR as biomarkers of response to erlotinib in Canadian Cancer Trials Group study BR.21. J Clin Oncol 26: 4268-75, 2008.

For a complete listing of all Canadian Cancer Trials Group Group publication, as well as presentations, abstracts, conference proceedings, etc., please visit our publications website at